Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13367MR)

This product GTTS-WQ13367MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13367MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8311MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ5367MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ6276MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ111MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ7172MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ1613MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ7258MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ10109MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LA480
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW